The manner by which the trans-acting factor encoded by the 1,828-base-pair (bp) BamHI DNA fragment of hepatitis B virus (HBV) suppresses the production of human beta interferon was determined. Steady-state levels of RNA specific for human beta interferon were decreased in cells that contained the 1,828-bp BamHI DNA fragment of HBV. The reduced accumulation of interferon-specific RNA was due to an inhibition of transcription of the interferon gene by the HBV trans-acting moiety. The expression of the interferon gene that is under the control of a heterologous promoter such as the simian virus 40 early promoter was not altered by the presence of the 1,828-bp BamHI HBV DNA fragment. In contrast, the HBV moiety inhibited the expression of the cat gene, whose expression is controlled by the regulatory DNA region of the human beta interferon gene. These results indicate that the HBV trans-acting moiety suppresses the expression of the human beta interferon gene at the transcriptional level by interacting with the regulatory DNA sequences 5' to the coding sequences for beta interferon.
Hepatitis B virus (HBV) is a small enveloped DNA virus that is an etiological agent of acute and chronic hepatitis in humans (10, 34) . The HBV genome, which is partially double stranded, consists of four open reading frames (ORF). The largest ORF encompasses most of the HBV genome and encodes the DNA polymerase (2, 35) . The smallest ORF, designated X, has the potential to encode a protein of 154 amino acids that may be a regulatory protein for gene expression, since it has the capability to transactivate both viral and cellular enhancers (30, 33, 38) . Another ORF encodes the HBV surface antigens that presumably function in the attachment of the virus to cell surfaces (5, 39) . Two proteins, the core antigen and the e antigen, are encoded by ORF C (20) . The core antigen appears to be retained intracellularly for the assembly of virions, whereas the e antigen is secreted (24, 26) . The function of the e antigen in infection by HBV is unknown, but this antigen does not appear to be crucial for viral replication (4) .
The factors that play a role in the development and maintenance of chronic HBV infections are unclear but could involve defects in natural host defenses, such as interferon. Although active viral replication occurs in chronic HBV carriers, serum interferon has not been detectable (17, 19, 32, 36, 42) . Interferon-inducible responses, such as enhanced expression of class I human leukocyte antigens on hepatocyte membranes and increased production of cellular 2',5'-oligoadenylate synthetase, are not observed in many chronic HBV carriers (18, 25, 27) . Lastly, peripheral blood lymphocytes from individuals with chronic hepatitis produce less interferon than do such lymphocytes from uninfected controls when stimulated in vitro with viruses (36) . These observations have led to the speculation that a defect in the ability to produce interferon may be involved in the development of chronic HBV infections (9) .
Recently, we have demonstrated that the 1,828-base-pair (bp) BamHI HBV DNA fragment that contains ORF C 94305.
suppresses the production of cloned human beta interferon (37) . The suppression of the synthesis of the beta interferon occurs via an HBV trans-acting factor and is alleviated by the introduction of a frameshift mutation within the HBV core antigen gene. However, the stage of synthesis of the beta interferon that is inhibited by the trans-acting HBV factor is unclear. We now report that the HBV trans-acting inhibitory factor suppresses the induction of the human beta interferon gene by poly(I)-poly(C) at the level of transcription by interacting, directly or indirectly, with a 353-bp sequence containing the regulatory elements that function in the induction of the human beta interferon gene.
MATERIALS AND METHODS
Plasmids. Various cloned fragments of HBV subtype adw (8) (Fig. 1) were cloned into the BamHI site of either the bovine papillomavirus (BPV) vector pdBPV-1 or pBI, a BPV plasmid containing the 1.6-kilobase (kb) Hindlll human beta interferon gene fragment (37) . Details of the construction of these plasmids are described elsewhere (37) . Briefly, the cloning of the 1,828-bp BamHI HBV DNA fragment (map position 1400 to 28) into both pdBPV-1 and pBI yielded pBHC and pBHCI, respectively. The 2,755-bp BgII HBV DNA fragment (map position 2429 to 1984) was cloned into the BamHI site of pBI, creating pBHSI. Plasmid pBIHCdTaql is identical to pBHCI except than an insertion mutation at the TaqI site (map position 2014) that is within the HBV core antigen gene was created as described elsewhere (37) . The insertion mutation resulted in the destruction of the TaqI site in the HBV core antigen gene and in a shift in the ORF.
Other plasmids used in this study were pTWU54, containing the cat structural gene that is controlled by the 353-bp regulatory elements involved in the expression of the human beta interferon gene (r-IFNR-cat) (38) , and pSVI911, containing the PvuII-HindIII simian virus 40 (SV40) DNA fragment including the early promoter fused to the HindIl human beta interferon fragment that carries the coding sequence and the 3' nontranslated region up to the poly(A) site (21 described by Twu and Schloemer (38) . Control cells were treated in the same manner, except that poly(I)-poly(C) was omitted. Interferon was assayed by determining antiviral activity (inhibition of cytopathic effect) against vesicular stomatitis virus (37) . Assays for human interferon were conducted with human WISH cells as the indicator cells. CAT assays. Cells were harvested and chloramphenicol acetyltransferase (CAT) assays were performed as described by Gorman et al. (14, 15) . Briefly, cells were pelleted, suspended in 0.25 M Tris hydrochloride (pH 7.8), and disrupted by freezing-thawing. The protein concentrations of cell lysates were determined, and CAT assays were performed with the same amount of total protein for all samples in an individual experiment. CAT activity was determined as described previously and is expressed as percent acetylation (38) .
Isolation of DNA. Total cellular DNA was extracted from cells by the modified method of Colbere-Garapin et al. (7) . Cells were lysed with 0.2 M Tris hydrochloride (pH 8.5) containing 100 mM EDTA, 100 mM NaCl, 1% sodium dodecyl sulfate, and 100 p.g of proteinase K per ml. The cell lysate was extracted with phenol-chloroform. After dialysis against TE buffer (22) , the DNA preparation was treated for 30 min at 37°C with DNase-free RNase at a final concentration of 10 jig/ml. After extraction with phenol-chloroform, the DNA was precipitated by ethanol and suspended in TE buffer.
Isolation and analysis of RNA. Total RNA was isolated from cells by using guanidium thiocyanate and by pelleting through a pad of 5.7 M CsCl as described by Sachstein and Colten (29) . RNA was stored as a precipitate in ethanol until use. RNA was analyzed by either Northern (RNA) blotting or dot blotting. For Northern blots, RNA was electrophoresed in a 1.5% formamide-agarose gel and transferred to Nytran membranes. Alternatively, RNA samples were applied to Nytran membranes with a Bio-Dot apparatus (BioRad Laboratories). Hybridizations were accomplished by standard procedures with DNA probes labeled with 32P by nick translation (22) . DNA probes were the 1.6-kb HindIll human beta interferon gene (37) , murine interferon cDNA (13) , or actin cDNA (6).
Nuclear transcription assays. Cells (2 x 107) were incubated on ice for 5 min in 10 mM Tris hydrochloride (pH 7.4) containing 10 mM NaCI, 3 mM MgCI2, and 0.5% (vol/vol) Nonidet P-40 (lysis buffer). The mixture was centrifuged at 500 x g for 5 min, and the pellet containing nuclei was washed with lysis buffer. The pellet was suspended in 50 mM Tris hydrochloride (pH 8.3) containing 5 mM MgCl2, 0.1 mM EDTA, and 40% glycerol.
Transcription of nuclei with 0.2 mCi of [ot-32P]UTP was performed essentially as described by Velcich and Ziff (40) , whereas isolation of resulting labeled RNA was performed as described by McKnight and Palmiter (23) . Nuclei (5 x 106) were mixed with 100 jl of reaction buffer (10 (35) . For determination of the step in the synthesis of human beta interferon that was being suppressed by HBV, total cellular RNA was prepared from these transformants, electrophoresed on agarose gels, and analyzed by Northern hybridization with the human interferon gene as the probe. As controls, RNAs from murine C127 cells and from MG63 cells, human osteosarcoma cells that are known producers of interferon (44) , were also analyzed.
Untreated C127-pBI cells contained low levels of human beta interferon RNA, which increased dramatically following treatment of the cells with poly(I)-poly(C) (Fig. 2A) . Similar results were observed when RNA isolated from C127-pBHSI cells was analyzed. In contrast, C127-pBHCI cells, which contained the 1,828-bp BamHI segment of HBV DNA, possessed vastly reduced levels of human beta interferon RNA when left untreated or when treated with poly(I)-poly(C). Murine C127 cells, which produced murine interferon upon treatment with poly(I)-poly(C) (37), did not synthesize RNA that hybridized to the human interferon gene probe. Poly(I)-poly(C)-treated MG63 cells contained RNA that reacted with the gene probe. Figure 2B demonstrates the results of dot blots to detect RNA specific for murine beta interferon and murine actin in the various transformed C127 cell lines. In contrast to the inhibition of accumulated levels of RNA specific for human beta interferon, the levels of RNA specific for murine beta interferon and murine actin were not affected by the presence of either HBV DNA fragment.
Inhibition by HBV of transcription of the interferon gene. The reduced levels of steady-state human beta interferon RNA in the presence of the 1,828-bp BamHI HBV DNA could be due to inhibition of the initiation of transcription or to a defect in the stability of the human beta interferon RNA. To distinguish between these possibilities, we performed nuclear transcription experiments with nuclei from C127-pBI cells and C127-pBHCI cells. In addition, nuclei were isolated from C127-pBIHCdTaqI cells, which contain a plasmid that is identical to pBHCI except that a frameshift mutation has been introduced at the TaqI site within ORF C of the HBV DNA. Previous studies have shown that this frameshift mutation results in the loss of the ability of the HBV DNA fragment to inhibit the production of human beta interferon (35) .
Treatment of C127-pBI cells with poly(I)-poly(C) resulted in a significant increase in the rate of transcription of the human interferon gene (Table 1) ' Nuclei were isolated from C127 cells transformed with the indicated plasmids 8 h after treatment of the cells with poly(l)-poly(C). RNA transcripts were elongated in vitro for 30 min with I32PIUTP. The resulting labeled RNA was isolated and treated with DNase prior to hybridization to human beta interferon DNA that had been immobilized on Nytran membranes. The amount of radioactively labeled RNA that had bound to the membranes was quantitated by liquid scintillation counting.
expression of a heterologous gene whose expression is under the control of the human beta interferon regulatory region, we used a plasmid (pTWU54) that contains the cat gene driven by the interferon regulatory region. Previous studies have indicated that poly(I)-poly(C) treatment of cells transfected with pTWU54 results in increased expression of CAT activity (38) . Vero cells were cotransfected with the test plasmid (pTWU54) and pUC9 derivatives containing various HBV DNA fragments. After transfection, cells were treated with poly(I)-poly(C) prior to analysis of CAT activity ( Fig. 3 and Table 2 ).
The low levels of CAT activity in cells containing pTWU54 and pUC9 increased upon treatment with poly(I)-poly(C) by an average of 5.5-fold. Extracts Effect of HBV on the stability of interferon RNA. To investigate the possibility that the HBV trans-acting inhibitory factor can alter the levels of human beta interferon RNA by affecting the stability of the RNA, we examined the effect of the HBV trans-acting inhibitory factor on the expression of the human beta interferon gene when controlled by a heterologous promoter. pSVI911 contains the human beta interferon gene whose expression is governed by the SV40 enhancer and early promoter elements (21) . C127 cells were cotransfected with pSVI911 and either the BPV plasmid containing the 1,828-bp BarnHI HBV DNA segment (pBHC) or the BPV vector alone (pdBPV-1). A plasmid carrying the gene encoding neomycin resistance was also present in each transfection. Clones of cells from each transfection were isolated on the basis of the transformed phenotype and resistance to the drug G418. Each focus was expanded and examined for the production of human beta interferon and for the presence of the interferon gene and the gene for the HBV core antigen ( Table 3) .
All of the clones contained the SV40-interferon fusion gene as well as the BPV plasmids. The SV40-interferon gene was integrated into the chromosome at approximately 2 to 5 copies per cell, whereas the BPV-containing plasmids were present at 20 to 25 copies per cell (data not shown). The presence of the 1,828-bp BamHI HBV DNA fragment had no effect on the production of human beta interferon when this gene was controlled by the SV40 regulatory elements.
DISCUSSION
Individuals who are chronically infected with hepatitis B virus have a poor response in the synthesis of interferon and interferon-inducible enzymes (17-19, 25, 27, 36) . Previously we demonstrated that the expression of cloned human beta interferon was affected by the presence of the HBV genome (37) . Specifically, an as-yet-unidentified trans-acting factor encoded by the 1,828-bp BamHI HBV DNA segment that contains ORF C inhibited the production of human beta interferon. The experiments reported here confirm and extend these observations by determining the basis for this inhibition.
The suppression of the production of human beta interferon by the HBV trans-acting moiety is due to reduced steady-state levels of interferon-specific RNA. This reduction in RNA levels, which is specific for human beta interferon RNA, is a result of inhibition of the transcription of the interferon gene. In support of this contention are the following observations. Results of nuclear transcription experi- " Transfections were performed as described in the legend to Fig. 3 with equal amounts of the indicated plasmids and of pTWU54.
ments indicated that very little human beta interferon RNA was transcribed in poly(I)-poly(C)-treated C127-pBHCI cells, which contained the 1,828-bp BamHI HBV DNA fragment. Moreover, the HBV trans-acting factor appeared to have no effect on the stability of RNA specific for beta interferon, since the production of beta interferon in the presence of this trans-acting factor was normal when the expression of this gene was controlled by a heterologous enhancer-promoter (the SV40 regulatory elements). Lastly, the HBV trans-acting factor was able to inhibit the expression of a heterologous gene, the bacterial cat gene, that was driven by the regulatory region of DNA that borders the 5' end of the coding sequence of the human beta interferon gene. This inhibition was observed when either the entire 3.2-kb HBV DNA fragment or the 1,828-bp BamnHI HBV DNA fragment was used as the source of the HBV transacting inhibitory factor. It is of interest to note that the expression of the cat gene under the control of the interferon regulatory elements is inhibited by the presence of the entire HBV genome. In addition to containing the 1,828-bp BamHI segment, which encodes the inhibitory factor, the HBV genome contains ORF X. We showed previously that the product of ORF X has the ability to transactivate the expression of the cat gene whose expression is controlled by the interferon regulatory elements (38) . The observation that inhibition of CAT activity occurs in the presence of the entire HBV genome would indicate that the negative effect of the trans-acting factor encoded by the 1,828-bp BamHI fragment is dominant over the positive effect of the X antigen. Another possibility that is consistent with the above-described finding is that the HBV trans-acting inhibitory factor inhibits or down-regulates the expression of the X gene product, an event that would result in the production of mainly the trans-acting inhibitory factor. Experiments to distinguish between these possibilities are currently being performed.
As noted previously, the identity of the HBV trans-acting factor that inhibits the expression of the human beta interferon gene is unknown. The 1,828-bp HBV DNA fragment used in these studies contains (i) the intact ORF C, (ii) the core promoter that is weakly active in nonhepatic cells, such as HS27 cells, rat fibroblast cells, and HeLa cells, and (iii) the modified polyadenylation signal, AUUAAU, at the end of ORF C (1, 28). Thus, it is conceivable that the HBV trans-acting inhibitory factor is a gene product of ORF C.
These data suggest that the HBV trans-acting inhibitory factor prevents transcription of the beta interferon gene by interacting directly or indirectly with the 353-bp DNA region that is responsible for the induction of beta interferon in response to either viral infection of cells or treatment of cells with synthetic double-stranded poly(I)-poly(C) (11, 45) . A 40-bp region, designated the interferon regulatory element, is sufficient for the induction of the human beta interferon gene in C127 cells and is located within the 353-bp DNA region that was used to control the expression of the cat gene in pTWU54 (11) (12) (13) 45) . The interferon regulatory element contains an enhancer that is composed of two positive regulatory domains and one negative regulatory domain (11, 12) . DNase footprinting experiments show that a protein(s) binds to the negative regulatory domain (44) . Presumably during induction of the interferon gene by poly(I)-poly(C) the protein binding to the negative domain is removed and other proteins then bind to the positive regulatory domains. It is unclear how the HBV factor prevents transcription of the interferon gene. The HBV trans-acting inhibitory factor may bind to the negative regulatory domain of the interferon regulatory element in an irreversible manner so as to prevent the binding of proteins to the positive regulatory domains during induction of the interferon gene by poly(I)-poly(C). Alternatively, the HBV trans-acting inhibitory factor may interfere with cellular processes that are involved in the removal of cellular proteins from the negative regulatory domain during induction of the gene by poly(I)-poly(C) or may inhibit the action of the positively acting cellular factors. Further experiments are needed to clarify the mechanism of inhibition of transcription by the HBV factor.
It is possible that a reduction in the amount of interferon synthesized during the acute stage of an HBV infection could be a predisposing factor for the establishment of a VOL. 63, 1989 on July 6, 2017 by guest http://jvi.asm.org/ Downloaded from chronic HBV infection. Interferons are cellular proteins that represent the initial response to viral infections (31) . In addition to their antiviral activity, interferons have several properties that may play a role, via immune mechanisms, in the recovery from acute viral infections. Interferons increase the expression of class I human leukocyte antigens on membranes of infected cells (25) , activate natural killer cell activity (41) , and enhance the response of cytotoxic T lymphocytes to virus-infected cells (3) . Therefore, a defect in the synthesis of interferons during an acute HBV infection could hinder the activities of antigen-producing cells and of cytotoxic T lymphocytes to such an extent as to allow continued viral infection and the development of a chronic HBV infection. It is also possible that the HBV inhibitory factor could suppress these interferon-inducible responses.
